IPO Timeline
Broker Results (T-2)
2023-04-25
Some brokers release in afternoon
Grey Market (T-1)
2023-04-26
Afternoon
HKEX Allotment (T-1)
2023-04-26
Evening
Registrar Allotment (T-1)
2023-04-26
Evening
Listing Day (T)
2023-04-27
First day of trading
Company Overview
| Stock Name | 梅斯健康 |
| Stock Code | 02415 |
| Company Full Name | 梅斯健康 |
| Industry | 軟件服務 |
| Principal Activities | 公司于中國運營在線專業醫師平臺。 |
| Listing Date | 2023-04-27 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國上海市松江區莘磚公路258號34號樓18樓 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | https://ir.medsci.cn/zh_cn/ |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism |
To be extracted
|
| Offer Price | HK$ 9.10 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 51.6% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 60,778,900 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 9.2 |
| First Day Open | HK$ 8.85 |
| First Day Change | 1.10% |
| First Day Volume | 6280550.0 |
| First Day Turnover | 56732200.0 |
Use of Proceeds
| Use of Proceeds | 1、約45%所得款項凈額,或約242.19百萬港元預計將用于業務擴張。
2、約35%所得款項凈額,或約188.37百萬港元預計將用于進一步的技術開發。
3、約15%所得款項凈額,或約80.73百萬港元預計將用于我們的潛在投資及收購或與能夠與我們業務產生協同效應的公司建立戰略聯盟。
4、約5%所得款項凈額,或約26.91百萬港元預期將用作營運資金及一般企業用途。 |
Underwriting Syndicate
Joint Sponsors (2)
中国国际金融香港证券有限公司 CE AEN894
麦格理资本股份有限公司 CE AAC534
Overall Coordinators (2)
中国国际金融香港证券有限公司 CE AEN894
麦格理资本股份有限公司 CE AAC534
Joint Bookrunners (11)
中国国际金融香港证券有限公司 CE AEN894
麦格理资本股份有限公司 CE AAC534
建银国际金融有限公司 CE AJO225
海通国际证券有限公司 CE AAF806
安信国际证券(香港)有限公司
Dragonstone Capital Management Limited CE BGM303
中国光大证券(香港)有限公司 CE AAW536
第一上海证券有限公司 CE ABV488
首控证券有限公司
中泰国际证券有限公司 CE BAA855
富途证券国际(香港)有限公司 CE AZT137
Joint Lead Managers (14)
中国国际金融香港证券有限公司 CE AEN894
麦格理资本股份有限公司 CE AAC534
建银国际金融有限公司 CE AJO225
海通国际证券有限公司 CE AAF806
安信国际证券(香港)有限公司
Dragonstone Capital Management Limited CE BGM303
中国光大证券(香港)有限公司 CE AAW536
第一上海证券有限公司 CE ABV488
首控证券有限公司
中泰国际证券有限公司 CE BAA855
富途证券国际(香港)有限公司 CE AZT137
盈立证券有限公司 CE BJA907
元库证券有限公司 CE BLN458
利弗莫尔证券有限公司 CE BJN764
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
| 1 |
Harvest International Premium Value (Secondary Market) Fund SPC |
109,898,425 HKD |
— |
18.08% |
— |
6 months |
2023-10-27 |
| 2 |
安吉国融创业投资有限公司 |
23,548,525 HKD |
— |
3.87% |
— |
6 months |
2023-10-27 |
| 3 |
安吉国融建设有限公司 |
47,099,325 HKD |
— |
7.75% |
— |
6 months |
2023-10-27 |
| 4 |
安吉交投实业发展有限公司 |
23,548,525 HKD |
— |
3.87% |
— |
6 months |
2023-10-27 |
| 5 |
安吉七彩灵峰乡村旅游投资有限公司 |
15,699,775 HKD |
— |
2.58% |
— |
6 months |
2023-10-27 |
| 6 |
广发全球资本有限公司 |
94,198,650 HKD |
— |
15.50% |
— |
6 months |
2023-10-27 |
Directors & Management
| Chairman | 張發寶 |
| Company Secretary | 楊春,關秀姸 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | Microhealth Limited(29.30%);Dtx Health Limited(23.32%);Dragon Step Ventures Limited(8.87%);Meiyue Limited(6.89%);意像架構投資(香港)有限公司(6.21%) |
Disclaimer & Risk Warning
Site Nature: This website (cibo.qizai.ai) is an independent technology product showcase platform established by Panda Securities Limited (CE Number: BNC380). This website itself and all content displayed herein do not constitute and are not involved in any regulated activity or licensed service.
Not Investment Advice: The data on this page is automatically extracted from prospectus PDFs by AI and may contain omissions or errors. All information and data on this page are sourced from prospectuses and related historical documents, are not real-time data, and will not be automatically updated, reflecting historical information at the time of prospectus publication. All content is provided solely for AI tool analysis learning exchange and technical reference purposes, and absolutely does not constitute any investment advice, offer to buy or sell, solicitation, recommendation, or guarantee. The output of this AI analysis tool should not be interpreted as investment opinion.
Decision Responsibility: Users should make investment decisions based on their own independent judgment and consult independent licensed financial advisors when needed. Neither the Company nor this AI analysis tool shall bear any responsibility for any investment decisions made by users based on the information on this page.
Separation from Panda Securities Official Website: The content of this website is strictly distinct from the SFC-regulated licensed services provided by Panda Securities' official website (fafa.hk). No securities trading or account opening or other regulated operations can be conducted through this website.
Panda Securities Limited is a licensed corporation regulated by the Hong Kong SFC (CE Number: BNC380) and a Hong Kong Exchange Participant (Participant ID: 02229). Use of this website constitutes acceptance of this disclaimer.